622 related articles for article (PubMed ID: 27835874)
1. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
3. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
5. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
6. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
7. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
[TBL] [Abstract][Full Text] [Related]
8. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
Bruno R; Alì G; Poma AM; Proietti A; Libener R; Mariani N; Niccoli C; Chella A; Ribechini A; Grosso F; Fontanini G
J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
[TBL] [Abstract][Full Text] [Related]
9. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
10. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
De Rienzo A; Richards WG; Yeap BY; Coleman MH; Sugarbaker PE; Chirieac LR; Wang YE; Quackenbush J; Jensen RV; Bueno R
Clin Cancer Res; 2013 May; 19(9):2493-502. PubMed ID: 23493352
[TBL] [Abstract][Full Text] [Related]
11. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics.
Bertero L; Righi L; Collemi G; Koelsche C; Hou Y; Stichel D; Schrimpf D; Flucke U; Petersen I; Vokuhl C; Fröhling S; Bironzo P; Scagliotti GV; Cassoni P; Papotti M; von Deimling A
J Mol Diagn; 2021 Jul; 23(7):834-846. PubMed ID: 33887463
[TBL] [Abstract][Full Text] [Related]
14. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
15. Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
Wright CM; Kirschner MB; Cheng YY; O'Byrne KJ; Gray SG; Schelch K; Hoda MA; Klebe S; McCaughan B; van Zandwijk N; Reid G
PLoS One; 2013; 8(8):e70940. PubMed ID: 23976967
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
17. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
Fujii M; Fujimoto N; Hiraki A; Gemba K; Aoe K; Umemura S; Katayama H; Takigawa N; Kiura K; Tanimoto M; Kishimoto T
Cancer Sci; 2012 Mar; 103(3):510-4. PubMed ID: 22146010
[TBL] [Abstract][Full Text] [Related]
18. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
[No Abstract] [Full Text] [Related]
19. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
